Alaunos Therapeutics (TCRT) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
XORTX Therapeutics is the larger company by market cap ($2.6 million vs $2.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TCRT | XRTX |
|---|---|---|
| Share price | $0.7858 | $1.41 |
| Market cap | $2.30M | $2.56M |
| 1-day change | +0.61% | -23.78% |
| Forward P/E | — | 1.76 |
| EPS (TTM) | $-1.76 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.50 | $7.05 |
| 52-week low | $0.72 | $1.36 |
| Distance from 52-week high | -82.54% | -80.00% |
| Average volume | 797.20K | 376.30K |
| Shares outstanding | 2.93M | 1.82M |
| Employees | 1 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alaunos Therapeutics
TCRT stock →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
TCRT vs XRTX FAQ
Which is bigger, Alaunos Therapeutics or XORTX Therapeutics?
XORTX Therapeutics (XRTX) is larger, with a market capitalization of $2.56M compared with $2.30M for Alaunos Therapeutics (TCRT).
Are Alaunos Therapeutics and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.